60 Degrees Pharmaceuticals Inc
$1.65
+0.0700 (4.43%)
Developing therapeutic innovations that can significantly improve and extend people’s lives
Join the 60 Degrees Pharmaceuticals Inc Investor Community
Get the latest news and company updates delivered straight to your inbox. Subscribe for free to stay ahead of the story and follow 60 Degrees Pharmaceuticals Inc as new developments unfold.
Company Overview
60 Degrees Pharmaceuticals (60P) is a growth-oriented biotechnology company developing new therapies for vector-borne diseases. The Company markets the FDA-approved antimalarial ARAKODA® (tafenoquine) and is advancing tafenoquine into new indications, including babesiosis, a tick-borne infection with no approved treatments. Clinical trial data from ongoing studies will be generated in the second half of 2026, after which the company will refine its strategy for an FDA regulatory submission.
Value Proposition
60P is addressing unmet medical needs in vector-borne disease through the development and commercialization of small-molecule therapeutics with established safety profiles. Building on its FDA-approved malaria prophylaxis ARAKODA® (tafenoquine), the Company is advancing tafenoquine into new indications, notably babesiosis, a rapidly growing tick-borne infection with no FDA-approved treatments.
In October 2025, 60P reported no Babesia infection detected in the first patient to complete therapy in its relapsing babesiosis study, an encouraging early signal supporting tafenoquine’s potential to address this growing unmet need.
Initial research estimated the U.S. babesiosis market at up to a maximum of 380,000 addressable patients annually, representing up to $245 million in peak yearly sales and up to $1.1 billion in cumulative revenue potential through 2035. Supported by its existing commercial infrastructure and seasoned leadership team, 60P offers investors a capital-efficient path to expansion and meaningful upside potential in a high-growth vector-borne disease market.
60P is also testing the viability of developing Australian Chestnut Extracts as a botanical product for non-prescription use in the U.S. market, may seek to develop and license other molecules in the future.
On the commercial front, 60P is scaling ARAKODA® sales, with 2026 initiatives including expansion of the inside sales team, enhanced digital marketing, broader patient access through GoodRx, and a new travel-focused telehealth partnership designed to reach international travelers prior to departure.
About Babesiosis
- Tick-borne disease caused by protozoan parasites of the genus Babesia
- Invades red blood cells, causing:
- Non-specific flu-like symptoms
- Anemia
- Death (1.6% mortality rate in hospitalized patients/10% in those with cardiac complications)
- May be refractory to treatment in immunosuppressed patients
- Hypothesized to prolong recovery time from chronic illnesses
- Common in Mid-West and Northeastern US
- Geographic range expanding and incidence increasing
- Common coinfection with Lyme disease (10% of cases)
Portfolio
Investor Presentation
Investment Highlights
ARAKODA® (tafenoquine) – Commercially Launched Antimalarial
- FDA-approved safe, long-acting, mechanistically differentiated anti-malarial, co-developed with U.S. Army
- 1,100+ patient exposures in 8+ published trials
- Commercially available in U.S. via network of major national distributors
- New 8-count bottle format launched June 2025 to expand market potential
- 2026 commercial expansion includes doubling inside sales capacity, enhanced digital marketing, a GoodRx partnership, and a new travel-focused telehealth channel via Runway Health
Advancing Tafenoquine for Babesiosis – a Significant Unmet Need
- No FDA-approved treatments currently exist for babesiosis
- Three clinical studies in babesiosis will yield initial data in late 2026
- Relapsing babesiosis highlights:
- First patient tested negative for infection using a highly sensitive, FDA-licensed assay
- Study designed to confirm high cure rates in immunosuppressed patients with relapsing disease – remaining enrolled patients to completed study in March 2026Company to set regulatory strategy in late 2026
Large and Growing Market Opportunity
- Initial estimate of U.S. babesiosis market was up to a maximum of 380,000 addressable patients annually
- Represents up to $245M in potential peak annual sales and up to $1.1B cumulative revenue through patent expiration in 2035
Seasoned Management Team and Board
- Profound clinical expertise in tafenoquine and related therapeutics
- Team has together led/managed six clinical trials
- Collectively led multiple pharmaceutical product approvals/ international pharmaceutical product launches
- Collectively led/provided guidance to multiple public & private entities
- Participated in/led multiple public listings
Buy ratings from Ascendiant & H.C. Wainwright with $17.60 median PT
Articles
Apr. 27, 2026 7 min read
60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is a Washington, D.C.-based specialty pharmaceutical company developing and commercializing treatments for vector-borne infectious diseases. Its lead commercial asset is ARAKODA® (tafenoquine), the only FDA-approved, broad-spectrum, once-weekly malaria prevention drug on the U.S. market, co-developed with the U.S. Army and commercially available since 2019...
Read MoreClinical Trial Pipeline Stages
| Drug Name | Stage |
|---|---|
| ArakodaDetailsMalaria | Approved |
| SJ733DetailsMalaria | Phase 2b |
| TAFENOQUINEDetailsBabesiosis | Phase 2a |
| TAFENOQUINEDetailsCOVID-19 | Failed |
Sign Up For SXTP Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Sixty Degrees Pharma (SXTP) is a client of RedChip Companies. SXTP agreed to pay RedChip Companies, Inc. a $9,500 monthly cash fee, beginning in March 2023, and $40,000 of Rule 144 stock (based on the 30-day average price after the IPO) for six months of investor awareness services. RedChip intends to and will, if possible, sell all of its shares immediately upon removal of the restriction, and you may be buying as RedChip is selling. SXTP also agreed to pay RedChip a one-time $70,000 fee for a national TV ad campaign aired weekdays from May 20 to June 7, 2024, and a $55,000 fee for a national TV ad campaign aired weekdays from July 28 to August 7, 2025.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.